A letter published in the The Lance by Dr Contreras and colleagues at the North London Blood Transfusion Centre commented that if "the true incidence of post-transfusion NANB hepatitis and its serious clinical sequelae are at a much lower level than reported from the USA, then screening of donations to reduce the incidence of NANB hepatitis may not be cost effective in the UK".